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Once belonging to science ﬁction, face transplantation is a clinical reality now. The con-
troversialﬁrstfacetransplantationinAmiens,Francein2005wasfollowedbysigniﬁcant
ethical debate among physicians, surgeons, scientists and bioethicists. The controver-
sies are being followed by cautious optimism and acceptance. An increasing number of
surgical teams are developing protocols of composite tissue transplantation. Twenty ﬁve
years after the birth of the American Society of Reconstructive Microsurgery (ASRM)
and during its 25th anniversary, the founding meeting of American Society of Recon-
structive Transplantation (ASRT) took place in 2009 to ofﬁcially introduce the birth of
a new ﬁeld that combines the two disciplines: transplantation and reconstructive micro-
surgery. It appears that the ﬁeld of composite tissue allotransplantation will continue to
grow for at least several years before more sophisticated means of replacing the dam-
aged tissues become available. This article takes a brief look at the evolution of organ
transplantation and reﬂects our viewpoint regarding the emerging ﬁeld of composite
tissue allotransplantation (CTA).
Early in the application of any new technology whether it be space travel or heart transplantation,
you cannot rely on statistics because there is not enough experience to provide a basis for statistical
analysis. As new treatments arise, that special problem of insufﬁcient numbers inevitably arrives for
each. .. . Flexibility and individual judgment must prevail for many years in any new ﬁeld.
Francis D. Moore, MD1
History of organ transplantation is quite remarkable. Perhaps no other surgical ﬁeld
started with an outlook of signiﬁcant constraints represented by limited donor pool, or
as a temporary solution to medical problems while awaiting more sophisticated means
of tissue replacement, and deep ethical challenges. Against the odds and despite being
one of the most controversial ﬁelds of surgery, transplantation has been one of the fastest
growing surgical specialties since its introduction in the mid-20th century. The ﬁrst organ
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transplantation by Dr Joseph E. Murray in 1954 was viewed as a rather unique option for
identicalsiblingsonly,foryears,grosslyunderestimatingthehistoricvalueoftheoperation.
The technical expertise in organ transplantation had been based on the pioneering
work of Alexis Carrel in early 20th century, who developed a safe and reliable method for
vascular anastomosis.2 It was not however until the early 1960s and remarkable advances in
“microsurgery” that “composite tissue transfer” came into the clinical arena.3 The second
challenge was to overcome the host immunological barrier, a battle that took almost “seven
black years” (1954-1961)1 to end. In just more than 7 years after the ﬁrst successful kidney
transplantation between identical twins in 1954,4 the advances in transplant immunology
and the advent of chemical immunosuppression opened the possibility of transplanting
tissues against the genetic barrier leading to the ﬁrst successful kidney transplant from
an unrelated donor in 1962. From the mid-1960s, an increasing number of surgeons,
physicians, and scientist began to expand the application of tissue transplantation to other
organs. Clinical liver (1963-1966), heart (1968-1973), lung, and pancreas transplantations
were important milestones in the evolution of organ transplantation and we feel that we are
going through another milestone in the ﬁeld of transplantation: the rise of the composite
tissue allotransplantation (CTA).
In the “hierarchy” of tissue and organ rejection, skin is the most vulnerable organ
for transplantation. In fact, the father of immune tolerance Sir Peter Medawar commented
on skin as a “non-starter” for a surgeon. The combination of microsurgery and available
regimensofchemicalimmunosuppressionledtomultipleexperimentsinCTAwithvarying
degrees of success. Despite the availability of technical expertise, obtaining an efﬁcient yet
nontoxic immunosuppressive regimen that could safely prevent rejection of the highly
antigenic tissues of multiple embryonic origins, typically including skin, muscles, and
nerves, delayed the progress of the ﬁeld until late 1990s.5
The ﬁrst successful hand transplantation by Professor Dubernard in 1998 was the
ﬁrst clinical application of CTA.6 Although revolutionary, this procedure raised remarkable
ethical controversies—the use of life-long immune suppressive medications for a non–
life-saving tissue. The timing could not have been worse; tissue engineering was going
through arguably the most exciting years since its inception and research teams around the
world had predicted engineering of human organs within 10 years. In spite of scientiﬁc
progress and encouraging early predictions, however, tissue engineering proved to be far
more challenging and even now appears remote from clinical application.
From 1998 to 2005, only a few centers around the world believed in and performed
composite tissue transplantation. It took a second event that led to the greatest excitement
about CTA ever. This event was the world’s ﬁrst face transplantation7—this time in the
setting of discouraging short-term outlook, declining interest, and funding of tissue engi-
neering projects.8 Following the initial mistrust, the world’s ﬁrst face transplantation truly
excited and energized clinicians around the world. In contrast to conventional “reconstruc-
tive” methods, CTA offers the only truly “restorative” procedures for the most disﬁgured
and functionally affected patients. Unlike a prosthesis that may partially return function to
an amputated arm, there is no functional prosthesis for replacement of the central facial
tissues. The results are remarkable, and these techniques are immediately available for
clinicians. Tailored immune-suppression regimens have acceptable rates of complications.
Since the founding meeting of the American Society for Reconstructive Transplan-
tation in July 2008, 2 face transplantation procedures have been performed in the United
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States.9,10 Currently,thereareapproximatelyadozenofcentersintheUnitedStatesthatare
in the process of preparation of their CTA program. Those who were against face transplan-
tation just a few years ago are now admitting that at the current age, it is perhaps the best
treatment option in many patients suffering from facial deformities and whom they have
treated for many years. At the same time, ﬁrst reports on transplanted organ tolerance seem
to be promising and perhaps achievable in composite tissue transplantation. Simultaneous
transplantation of multiple tissues (facial, upper and/or lower extremity) would enhance
the quality of life and functional status of polytrauma patients and would appear to further
justify life-long immunosuppression for the gained functionality.
We are living in the era of CTA rise. Throughout medical history, there come moments
when it is possible to perceive the end of one era and the start of a new one. It is our
prediction that until further advances in “tissue engineering” technology are made, the ﬁeld
of composite tissue transplantation continues to grow.
While we must beware the enthusiast who pushes his own operation or his favorite drug too hard,
we must equally beware the detached Olympian. The opinion of an inexperienced ethicist may be
ethically unacceptable.
Francis D. Moore, MD1
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